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Abstract
Background: Clusterin is a cytoprotective chaperone protein involved in numerous physiological processes,
carcinogenesis, tumor growth and tissue remodelling. The purpose of this study was to investigate whether
clusterin (CLU), an antiapoptotic molecule, could be a potential predictor molecule for ovarian cancer and whether
or not targeting this molecule can improve survival of ovarian cancer patients.
Methods: Clusterin expression was compared between ten primary and their recurrent tumors from same patients
immunohistochemically. We analyzed prognostic significance of CLU expression in another 47 ovarian cancer tissue
samples by immunohistochemistry. We used small interference RNA to knock down CLU in the chemo-resistant
ovarian cancer cell lines. KF-TX and SKOV-3-TX, paclitaxel-resistant ovarian cancer cells, were established from
parental KF and SKOV-3 chemo-sensitive cell lines, respectively. Either siRNA or second generation antisense
oligodeoxynucleotide against CLU (OGX-011), which is currently evaluated in clinical phase II trials in other cancer
s, was used to modulate sensitivity to paclitaxel (TX) in ovarian cancer cells in vitro. Cellular viability assay, FACS
analysis and annexin V staining were used to evaluate the comparative effect of CLU knocking down in ovarian
cancer cells.
Results: Immunohistochemical analysis of CLU expression in primary ovarian cancer tissue specimens and their
recurrent counterparts from same patients demonstrated higher expression of CLU in the recurrent resistant
tumors compared with their primary tumors. High expression of CLU by immunohistochemistry among 47 surgical
tissue specimens of early-stage (stage I/II) ovarian cancer, who underwent complete cytoreduction as a primary
surgery, significantly related to poor survival, while none of other clinicopathological factors analyzed were related
to survival in this patient cohort. Secretory CLU (s-CLU; 60 KDa) expression was upregulated in TX-resistant ovarian
cancer cells compared to parental cells. Transfection of siRNA or OGX-011 clearly reduced CLU expression. Cell
viability assay, FACS analysis and annexin V staining demonstrated that targeting CLU expression by siRNA or OGX-
011 sensitized ovarian cancer cells to TX.
Conclusion: We conclude that CLU could be a potential molecular target to predict survival while targeting this
s-CLU may improve survival of patients with ovarian cancer.
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Chemotherapeutic drug resistance is a critical problem
in cancer therapy as many tumors are intrinsically toler-
ant to some of the cytotoxic agents used, while others,
although they are initially sensitive, recur and eventually
acquire resistance to subsequent treatment with anti-
neoplastic agents [1].
Ovarian cancer is the fourth common cause of cancer-
related death in women because 75% of ovarian cancers
are detected as late-stage disease [2,3]. Nevertheless, after
optimal surgical debulking of the tumor and standard
chemotherapy, patients with advanced disease experience
5-year survival rate [4]. Despite the relative sensitivity of
ovarian cancer to chemotherapy, clinical chemotherapeu-
tic treatment often encounters drug resistance [5]. Devel-
opment of this acquired resistance represents the major
limitation to successful treatment. Consequently, there is
a pressing need to identify the mechanisms underlying
resistance in order to develop novel drugs to re-sensitize
tumor cells to primary chemotherapy.
Recently, histologic subtype has been recognized as one
of the key factors related to chemosensitivity in ovarian
cancer. Especially, clear cell carcinoma of the ovary,
which is recognized as a distinct histologic entity in the
World Health Organization classification of ovarian
tumors, demonstrates a distinctly different clinical beha-
vior from other epithelial ovarian cancers. Several studies
showed that patients with clear cell carcinoma had a
poor prognosis, partly due to a low response rate to che-
motherapy [3-5]. However, little is known about the
mechanisms of chemoresistance (intrinsic resistance) of
clear cell carcinoma [6]. Response to taxane/platinum in
clear cell carcinoma is still controversial. Reed et al. [7]
suggests that common resistance mechanism might be a
central determinant for response to current combination
therapy regardless of histologic type.
The cytoprotective chaperone protein, clusterin (CLU),
has been reported to be involved in numerous physiologi-
cal processes important for carcinogenesis and tumor
growth, including apoptotic cell death, cell cycle regula-
tion, DNA repair, cell adhesion, tissue remodeling, lipid
transportation, membrane recycling, and immune system
regulation [8]. CLU protein is commonly up-regulated by
chemotherapy and radiotherapy in cancer cells, and con-
tributes to cancer cell resistance in vitro and in various
animal models of cancer by blocking apoptosis [9]. Cyto-
plasmic CLU is consistently reported to be associated with
chemoresistance and it is present in a wide range of
advanced cancers as shown in human tumor tissues from
prostate [10,11], renal [12], breast [13], ovarian [14], colon
[15], lung [16], pancreas [17], cervix [18], melanoma [19],
glioma [20], and anaplastic large cell lymphoma [21].
Recent clinical trials using OGX-011, an antisense oli-
godeoxynucleotide specifically targeting CLU by
complementing CLU mRNA translation initiation site
have been launched [22]. OGX-011 potently inhibits
CLU expression and enhances the efficacy of anticancer
therapies in vitro and in vivo [23,16]. In addition to a
phosphorothioate backbone, OGX-011 incorporates a 2’-
methoxyethyl modification to the ribose moiety on the
flanking four nucleotides. This allows formation of RNA
duplexes with higher affinity for improved potency,
increases nuclease resistance prolonging tissue half-life
[24] and decreases toxicity with less nonspecific immune
stimulation than unmodified phosphorothioate antisense
[25].
In ovarian cancer, very limited number of studies has
directly examined the effect of altering CLU expression
on cell death and survival. Thus, prognostic significance
of CLU expression in ovarian cancer patients remains
controversial [26-29]. To establish the clinical signifi-
cance of CLU as a potential molecular target to predict
survival in ovarian cancer patients, we conducted this
study.
Methods
Cell line
Human ovarian cancer cell line, KF, was provided as a
generous gift by Dr. Yoshihiro Kikuchi, National Defence
Medical College, Saitama, Japan. Another ovarian adeno-
carcinoma cell lines, SKOV-3 and OVK-18 cells, were
p u r c h a s e df r o mA T C C ,a n dc l e a rc e l lc a r c i n o m ac e l l
lines, KOC-7c and TU-OC-1, were provided as a gener-
ous gift by Dr. Junzo Kigawa, Tottori University, Japan.
All cell lines were maintained in RPMI-1640 supplemen-
ted with 2 mM L-glutamine, and 10% FCS (Sigma, St.
Louis, MO, USA) OVK18 cells, maintained in DMEM
supplemented with 2 mM L-glutamine and 10% FCS
(Sigma). Both KF-TX and SKOV-3-TX clone were estab-
lished from parental cell lines KF and SKOV-3, respec-
tively by maintaining each clone in increasing sublethal
concentration of TX (up to 10 nM for KF-TX and 2 nM
for SKOV-3-TX) for more than ten months then IC50 of
each clone was determined by the viability assay after
three days treatment.
Antibodies and reagents
Mouse anti-human CLU (clone 41 D, Upstate Biotech-
nology, Lake Placid, NY, USA) was used at 1:1,000 dilu-
tion for western blotting. Immunoblotting detection was
done with anti-mouse secondary horseradish-peroxidase-
conjugated antibodies (Dako) diluted 1:2,000. TX was
supplied by Bristol-Myers Co. Ltd. (Japan). We then pre-
pared stock solution by diluting TX in the media at a
final concentration of 4 μM and further working dilu-
tions were carried out to reach the desired concentration.
Antisense oligodeoxynucleotide against CLU (OGX-011)
was provided by Oncogenex (Canada).
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To knock down the expression of CLU, siRNA or OGX-
011 was used in this study. Validated siRNA oligomers
directed against the s-CLU mRNA leader endoplasmic
reticulum signal peptide (s-CLU-siRNA) [30] and a con-
trol sequence which does not match any gene sequence
(Cont-siRNA) were synthesized by Ambion (USA): s-
CLU-siRNA, 5-GCG UGC AAA GAC UCC AGAAdTdT-
3 and 3-dTdTCGC ACG UUU CUG AGG UCU U-5;
Cont-siRNA, 5-GCG CGC UUU GUA GGA UUC
GdTdT-3 and 3-dTdTCGCGCG AAA CAU CCU AAG
C-5. s-CLU-siRNA or cont-siRNA were transfected into
ovarian cancer cells (10
5 cells/60-mm dish) using SiPORT
Neofex (Ambion; USA) at a final concentration of 200 nM.
KF-TX cells were cultured to 50% confluence. Transfec-
tion of OGX-011 was done twice using Effectine (Qiagen,
Hilden, Germany) according to the manufacturer’s
instructions. Twenty four hours after last transfection,
cells were treated with various concentration of TX for
72 h. Then cellular viability was evaluated.
Plasmids
pIRES/hygro and pIRES/hygro-full CLU expressing
vectors have been previously described [31]. Vector
expressing short hairpin RNA against CLU RNA
(CLU-shRNA; ver.3) was purchased from Upstate Bio-
technology (Lake Placid, NY, USA).
Generation of cell lines stably expressing s-CLU
OVK-18 cells were cultured to 50% confluence. Plasmid
DNA transfection was done using Effectine (Qiagen)
according to the manufacturer’s instructions. pIRES-
hygro or pIRES-CLU-hygro-transfected OVK18 cells
were selected in hygromycin (50 μg/ml; Sigma). Selected
colonies were screened by immunoblotting to identify
stable clones expressing s-CLU.
Cell viability assay
Cell viability was evaluated using cell counting kit
(CCK-8) (Dojindo, Kumamoto, Japan). Briefly, trans-
fected cells were pre-cultured in 96-well plate (3,000
cells/well) for 24 h. Seventy two hours after TX treat-
ment at the indicated doses, culture media were
replaced by the WST-8 reagent. Reduced WST-8 by the
cellular dehydrogenases turns into orange formazan.
Produced formazan is directly proportional to living
cells. Absorbance was measured at 450 nm by micro-
plate reader equipped by computer (NEC, Tokyo,
Japan).
Flow cytometry analysis
Following TX treatment, cells were trypsinized, washed
twice in phosphate-buffered saline (PBS) and cell cycle
phases were analyzed. Briefly, cells were fixed at 4°C
overnight in 70% ethanol. After washing with Ca2+-Mg2
+-free Dulbecco’s PBS, cells were treated with 0.1 μg/ml
RNase (Type I-A, Sigma), stained with 100 μg/ml propi-
dium iodide (PI; Sigma) for 20 min, filtered and kept on
ice until measurement. Cells were acquired by the FACS
calibrator (BD, Bioscience) and then analyzed using the
ModFit software (Verity software; ME, USA). Cell frac-
tions with a DNA content lower than Go/G1, the sub-
G0/G1 peak, were quantified and considered a marker
of the number of apoptotic cells.
Annexin V staining
After harvesting and washing as described above, the
cells were stained directly with PI at final concentration
of 10 μg/ml and 2% Annexin-V Flous (Roche, Basel,
Swizerland) in incubation buffer (10 mM Hepes/NaOH,
pH 7.4, 140 mM NaCl, 5 mM CaCl2) for 10 minutes.
Cells were acquired with the FACS calibrator (BD) after
setting the instrument with controls (non-treated,
stained cells) after two washes in PBS. In this experi-
ment, both cells with early apoptotic signals, stained
with annexin V, and cells with late death signals, stained
with PI, are all considered and quantified. Apoptotic
cells were analyzed using the CellQuest software.
Western blotting
Cell lysates were obtained by resuspending cells in RIPA
buffer (10 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton
X-100, 1% Nadeoxycholate (Kanto Chemical, Tokyo,
Japan) and 5 mM EDTA) supplemented with protease
inhibitors cocktail (Sigma, USA). Protein concentration
of subcellular fractions or whole cell lysates was deter-
mined by BSA assay using the BSA kit (Pierce, Rockford,
IL), then equal protein amounts were heated to 100°C for
5 min with SDS sample buffer (25 ml glycerol, 31.2 ml
Tris buffer, 7.5 ml SDS, a dash of bromophenol blue/100
ml) and run on 10% SDS-PAGE. Protein samples were
then blotted onto PVDF membranes (Immobolin P, Wat-
f o r d ,U K ) .T h em e m b r a n e sw e r ei n c u b a t e di nb l o c k i n g
solution (5% non-fat milk in PBS) for 1 h, then in pri-
mary antibody (anti-human CLU mAb at dillutin of
1:1000) overnight. After 3 × 10 min washes in TBS (0.1%
Tween-20 in PBS) the membrane was incubated for 1 h
at room temperature with horseradish peroxidase (HRP)-
linked IgG (1:2,000 dilution in T-TBS) followed by three
washes (10 min each) with T-TBS. Signal on membranes
was developed using ECL reagent (Amersham, USA) and
then was imaged with Polaroid imaging system (Amer-
sham,USA).
Immunohistochemistry
Immunohistochemical staining of CLU was performed
as previously described [19,32]. Detection of CLU was
performed using a commercial polyclonal anti-CLU
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S a n t aC r u zB i o t e c h n o l o g y ,S a n t aC r u z ,C A ,U S A ) .T h e
CLU antibody was used at 1:200 dilution for overnight
at 4°C. Negative control were obtained by omitting the
primary antibody. All slides were blindly evaluated for
CLU immunoreactivity and protein localization, without
knowledge of clinicopathological data.
Immunohistochemistry was performed in eight pairs of
primary and their recurrent matched tumors of ovarian
cancer specimens. All samples used were obtained from
surgically staged ovarian cancer patients. Primary surgery
was performed with the intention of maximal debulking.
The indication for secondary surgery was for single
recurrent tumor or interval debulking or secondary
debulking. All patients were treated with standard TC
regimen intravenously (TX; 175 mg/m
2, carboplatin;
AUC5) as first line chemotherapy. In this study, chemo-
responsive tumors were defined as tumors initially
responding to front-line chemotherapy with no relapse
for at least one year. Tumors showing no response or
recurring within one year after the first treatment were
defined as chemo-resistant.
For survival analysis, we divided 47 patients with
early-stage ovarian cancer into two groups based on
scoring as previously described [19]. All patients
received complete surgical staging and TX/platinum-
based adjuvant chemotherapy except stage Ia, non-clear
cell carcinoma.
Statistical evaluation
For in vitro experiments, statistical analyses were per-
formed using Minitab Release (Ver.12). Data are
expressed as mean ± S.E.M. One-way analysis of var-
iance was used to assess statistical significance between
means. Differences between means were considered sig-
nificant if p-values less than 0.05.
For statistical analysis of immunohistochemical
expression of CLU, correlation between the variables
and CLU immunoreactivity was analyzed using chi
square test or Fisher’s exact test. Patients’ survival was
calculated using Kaplan-Meier method. The significance
of the survival difference was examined by the log-rank
test. P < 0.05 was considered statistically significant. Sta-
tistical analyses were performed with the Statview soft-
ware package (SAS Institute, Inc, Cary, NC).
Results
CLU was upregulated in chemoresistant ovarian cancer
tissues
In a pilot experiment to check the relationship between
CLU overexpression and chemoresistance in clinical sam-
ples from ovarian cancer patients, we performed immuno-
histochemistry using CLU Ab. Table 1 summarized CLU
expression in eight primary ovarian cancer specimens
together with their recurrent matched tumors. Importantly,
primary chemo-responsive tumors showed either very lim-
ited or moderate CLU expression while CLU expression
decreased in the recurrent tumors from same patients after
chemotherapy course (Figure 1A.1,.2, respectively). In con-
trast, primary tumor samples from chemo-resistant cancers
showed either high or moderate CLU expression in the pri-
mary tumor, and CLU expression was still high or up-regu-
lated in the recurrent tumors (Figure 1A.3,.4, respectively).
Correlation of CLU expression with clinicopathological
factors and survival in the patients with early-stage
ovarian cancer
To assess any relationship between CLU expression and
clincopathological characteristics of ovarian cancer, we
used ovarian cancer tissue specimens from 47 patients with
early-stage ovarian cancer. Fifteen patients had stage Ia dis-
ease, twenty one stage Ic, one stage IIa, one stage IIb and
nine stage IIc. Clinicopathological characteristics of the
patients were shown in Table 2. Immunolocalization with
anti-CLU antibody largely showed positive staining in the
cytoplasm of cancer cells and occasionally positive in the
nucleus (Figure 1B). Among early stage ovarian cancer
patients who underwent complete cytoreductive surgery
including systematic pelvic and para-aortic lymphadenect-
omy, the association between the expression of CLU
Table 1 Clusterin expression pattern in the primary and recurrent ovarian cancers
Case (patient’s age) Chemo-senitivity primary tumor Persistent/recurrent t. histology FIGO stage
CLU intensity CLU intensity
1 (57) responsive ++ + serous IIIc
2 (48) responsive ++ + serous IIIc
3 (48) resistant + ++ serous IV
4 (53) resistant + +++ serous IV
5 (59) resistant + +++ serous IV
6 (52) resistant ++ +++ serous IIIc
7 (51) resistant N ++ serous IV
8 (55) resistant +++ +++ serous IIIC
N denotes negative staining, (+) denote weak staining (++) denote moderate staining, while (+++) denotes strong staining.
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gical factors revealed that age (p = 0.83), histologic subtype
(p = 0.32) were not related to CLU expression, while FIGO
stage showed the relation to CLU expression with marginal
significance (p = 0.09) (Table 3). The estimated 5-year
survival rate was 93.6% for patients with low CLU expres-
sion (n = 32), 78.8% for those with high CLU expression
among early stage patients (n = 15; Figure 1C.1). There was
a statistically significant difference of survival between the
groups (p = 0.04). Age (p = 0.65), FIGO stage (5-year
Figure 1 Immunohistochemical detetion of CLU in ovarian cancer tissue samples A. Representative images from immunohistochemistry
detection of CLU expression in primary tumor specimens from chemo-responsive tumor tissues (1). CLU staining is moderate or very low.
Recurrent tumor from the same patient also showed extremely limited staining of CLU (2). CLU staining in the primary tumor from chemo-
resistant tumor tissue (3) showed high CLU expression. Recurrent tumors from the same patients, however, showed high CLU expression after
chemotherapy (4).B. Representative photos of immunohistochemical expression of CLU in 47 tissue samples of ovarian cancer. 1) high
expression, 2) moderate expression, 3) low expression, and 4) negative expression. C. Kaplan-Meier survival curve according to CLU expression
(1), stage (2) and histology (3). Survival of patients with high and moderate expression of CLU showed significantly poor survival than that of low
and negative expression of CLU (p = 0.04).
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for stage Ic/II (n = 32); p = 0.18), and histological subtype
(survival rate was 100% for serous/endometrioid (n = 14);
and 84.2% for mucinous/clear cell (n = 33); p = 0.14),
which were not related to poor survival in this patient
cohort. (Figure 1C2, 1C3 and Table 3).
CLU is upregulated in chemoresistant ovarian cancer cell
lines
To verify our observation in the ovarian cancer cell lines
we further analyzed CLU expression in a panel of ovar-
ian cancer cell lines with different response pattern to
TX (different IC50) by western blot, revealed that all the
Figure 2 S-CLU is up-regulated in the chemo-resistant cells: A. Western blotting analysis of CLU in a panel of ovarian cancer cells. Equal
amount of proteins were loaded, resolved by SDS-PAGE and immunoprobed with anti-CLU mAb. S-CLU was found in the cells and media.
Some ovarian cancer cells express relatively high levels of CLU in comparison to immortalized non tumorigenic ovarian epithelial OSE cells. B.
Chemo-resistant KF-TX cells shows higher expression levels of CLU compared to parental KF cells. A similar result is found in SKOV-3 compared
to SKOV-3-TX cells. C. Quantitative PCR showing the difference in CLU transcript level between the TX-sensitive and TX-resistant clones in both
KF (left) and Skov-3 (right) systems.
Table 2 Clinicoparhological characteristics of patients
with early-stage ovarian cancer
Factor n %
Age
<50 24 51.1
> = 50 23 48.9
Histology
Serous/endometrioid 14 29.8
Mucinous/clear cell 33 70.2
Stage
Ia/b 15 31.9
Ic/II 32 68.1
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expression with the exception of OVK-18 cells, which
showed limited CLU expression. S-CLU expression was
relatively higher in cell lines with high IC50 of TX (Fig-
ure 2A and Table 4). We then established KF-TX cells
( I C 5 0=5 0 0n M )f r o mp a r e n t a lK Fc e l l s( I C 5 0=1 0 0
nM; see materials and methods). Importantly, KF-TX
showed higher expression of s-CLU in comparison with
parental KF cells (Figure 2B). To verify whether
increased s-CLU expression correlates with TX resis-
tance was not unique to KF cells, we similarly estab-
lished SKOV-3-TX (TX-resistant) from responsive
parental SKOV-3. Over-expression of s-CLU was also
observed in SKOV-3-TX compared to SKOV-3 (Figure
2B). Quantitative RT-PCR confirmed enhanced expres-
sion of s-CLU strictly correlated to mRNA expression in
both KF-TX and SKOV-3-TX cells when compared with
their parental cell lines (Figure 2C).
To investigate whether upregulation of s-CLU expres-
sion is a cause or a result of TX-induced resistance, both
parental KF and KF-TX cells were treated with TX in a
dose dependent fashion for 6 h. Sensitive KF cells rapidly
responded by increasing s-CLU expression level under
low doses of TX. In this experiment cellular viability
mainly decreased when TX dose surpassed IC50. KF-TX
cells already expressing higher CLU levels, did not
further express CLU following TX treatment (Figure 3A).
When we treated cells with TX up to 48 h, KF parental
cells progressively increased CLU expression levels up to
IC50 doses (100 nM) then CLU was down-regulated at
higher doses. On the other hand, CLU expression level
(already high) did not change in KF-TX cells. Again, only
at doses higher than IC50 (500 nM), CLU was down-
regulated (Figure 3B). S-CLU detected in cells’ medium
progressively decreased up to IC50 doses in the sensitive
cells suggesting its retention inside cells. However, secre-
tion of CLU into the media by resistant cells clearly
extended up to higher concentration of TX if compared
with parental cells. Considering that changes in CLU
expression seem independent of CLU mRNA, which did
not change significantly as indicated by real-time PCR
(data not shown), these results suggest that post-transla-
tional modification of CLU, including maturation and
secretion, may be altered in response to TX treatment.
Overexpression of s-CLU confers resistance to TX in vitro
To confirm the cytoprotective role of s-CLU in vitro,w e
established two cell clones stably expressing full-length
CLU (a gene able to express s-CLU) from the OVK18 cells
with low endogenous CLU, OVK18-s-CLU-1 (F-1) and
OVK18-s-CLU-2 (F-2). As shown in Figure 4A, very lim-
ited endogenous CLU is expressed and secreted by paren-
tal OVK18 cells, while CLU is detectable in both F-1 and
F-2 clones as precursor and secreted form in cell extract
and media. When cell viability of both clones was assayed
under progressively increasing TX doses, it was signifi-
cantly higher than mock controls (M-1 and M-2 (p < 0.05;
Figure 4B)). Figure 4C summarizes the result of FACS
analysis of F-1/F-2 clones compared to M-1/M-2. F-1 and
F-2 showed a significantly lower cell death as assessed as
sub-diploid peak, under TX stress when compared to M-1
and M-2. These data confirmed the cytoprotective effect
of s-CLU in ovarian cancer cells.
SiRNA against s-CLU and OGX-011 modulates sensitivity
to TX in KF-TX cells
To determine whether s-CLU protects ovarian cancer
cells from TX-induced cell death or not, siRNA oligo-
mers specific for exon II of CLU mRNA and OGX-011
were used to knock down CLU expression. TX resistant
ovarian cancer cells, KF-TX, were transfected either
with siRNA or OGX-011. CLU gene mRNA was amen-
able to siRNA transfection at doses of 100 and 200 nM
(Figure 5A.1) and to OGX-011 at doses of 400, 800,
1000 and 1200 nM as well (Figure 5A.2). We then con-
sidered 200 nM of siRNA and control siRNA and 1200
nM of OGX-011 and control oligodeoxynucleotide to be
used in further experiments because they maximally
reduced CLU expression.
To evaluate the benefits of targeting s-CLU in sensitiz-
ing ovarian cancer cells to TX, cellular viability of KF-TX
Table 3 Association between CLU expression and
clinicopathological factors in early-stage ovarian cancer
Factor CLU expression P-value
Low high
Age 0.83
<50 16 8
> = 50 16 7
Histology 0.32
Serous/endometrioid 11 3
Mucinous/clear cell 21 12
Stage 0.09
Ia/b 13 2
Ic/II 19 13
Table 4 List of ovarian cancer cells and their IC50 for TX
in a three days treatment experiment.
Histological type Cell line IC50 (TX; nM)
Serous KF 100
Serous KF-TX 500
Serous SKOV-3 20
Serous SKOV-3-TX 100
Serous OVK18 50
Clear cell TU-OC-1 6900
Clear cell KOC-7c 6700
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studied in both CLU-siRNA and control-siRNA (cont-
siRNA) transfected cells. Under these experimental con-
ditions Figure 5B.1 shows significant reduction in cell
viability of KF-TX, pre-treated with CLU-siRNA, under
different doses of TX than those pre-treated with con-
trol-siRNA then TX. Similarly, CLU knocking down by
siRNA significantly sensitized SKOV-3-TX cells (Figure
5B.2).
Moreover, sensitization to TX in KF-TX cells by CLU-
siRNA was further confirmed after time dependent fashion
of TX treatment by FACS analysis (at 36, 48 and 60 h; Fig-
ure 5C.1) where dead cells indicated by the sub diploid G0
cells. Further confirmation for differential apoptotic cells
was obtained by Annexin V staining (Figure 5C.2). These
data indicate that response to TX administration is
enhanced after CLU-siRNA transfection. In addition, a
dose dependent enhancement of apoptosis by TX in
Figure 3 Induction of CLU in a time and dose dependent fashion by TX. A. Western analysis showing s-CLU expression after 6 h treatment
with TX. Induction of s-CLU is evident in chemo-sensitive KF cells when treated with high doses of TX but not in KF-TX, in which the high levels
of s-CLU remained unchanged. Under these conditions, KF cells’ viability decreased. B. Western analysis showing s-CLU expression in cell extracts
(upper panel) and culture media (lower panel) after 48 h treatment with TX. CLU increased in TX-sensitive KF cells at different doses while CLU
secretion was inhibited. At difference, expression and secretion of CLU was unchanged in the TX-resistant cells. Only at very high concentrations
of TX a consistent down-regulation of s-CLU in the media was detectable. Ponceau S staining of the blot is provided to show equal loading of
the protein samples because Actin and tubulin are responding to TX. The data shown are representative of four independent experiments.
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laddering experiment (data not shown).
On the other hand, cellular viability was studied under
experimental conditions similar to this described above
except that OGX-011 was used to knock down CLU while
control oligodeoxynucleotide was used for control transfec-
tion. Figure 6A shows significantly less viability of KF-TX
cells pre-treated with OGX-011 and TX than those pre-
treated with control oligodeoxynucleotide and TX. Simi-
larly, sensitization to TX in KF-TX cells by OGX-011 was
further confirmed by FACS analysis (Figure 6B). Further
confirmation for differential apoptotic cells was obtained
by Annexin V staining (Figure 6C). Together, the afore-
mentioned data indicate that silencing s-CLU by specific
siRNA or OGX-011 enhanced TX toxicity in the ovarian
cancer cells.
Figure 4 Over-expression of CLU confers TX-resistance to OVK18 cells. A.Western blotting analysis showing the expression level of s-CLU and
mature secreted (40 kDa) CLU in the media in two recombinant OVK18 survivor clones F-1 and F-2 compared with two mock clones M-1 and M-2.
The pIRES-hyg-full-length-CLU cDNA expression vector was used for transfection experiments (see Materials and Methods). S-CLU was only detectable
in the media of F-1 and F-2 clones. B. Comparison of relative viability of clones F1 and F2 with regard to mock clones M1 and M2 in the presence of
different doses of TX. F-1 and F-2 clones show significantly increased viability. Each data point represents the mean of three experiments; bars denote
SD; * indicates difference from mock at P < 0.001. C. Quantification of the relative proportions of apoptotic cells by FACS analysis of M-1 and -2 and F-
1 and -2 clones in a time-course experiment. Cells were counted, divided into groups in triplicates and challenged by TX at 100 nm for the indicated
time periods. Cells were then acquired by FACS calibrator and the apoptotic sub-diploid peak was analyzed and quantified using the Cell-quest
software. Significant inhibition of TX-induced apoptosis was observed in the clones stably expressing CLU (F-1 and F-2).
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Page 9 of 14Knock-down of s-CLU enhanced cellular growth rate in
KF-TX and reduced clonogenic ability in parental KF cells
To understand more about how s-CLU contribute to the
fate of ovarian cancer cells, cellular growth rate follow-
ing CLU-siRNA transfection was studied in KF-TX cells.
Under these conditions, growth rate of KF-TX cells with
CLU knock-down significantly increased compared with
control siRNA-transfected cells (Figure 6D.1). Moreover,
we established stable CLU-silenced cell system using
CLU short hairpin expression vector (CLU-shRNA) in
Figure 5 Targeting CLU by siRNA or OGX-011 sensitizes ovarian cancer cells to TX treatment. A. Western blotting showing the efficacy of
siRNA transfection or OGX-011 in s-CLU depletion in KF-TX cells. (1) CLU expression after two sequential transfections with siRNA against CLU
(see materials and methods) at 100 and 200 nM are compared with control siRNA at 200 nM. Transfection at 200 nM knocked down about 90%
of target CLU (far right panel). The basic expression level without any transfection had not been affected neither by transfection reagents (data
not shown) nor by control siRNA transfection (far left panel). (2) CLU expression after two sequential transfections with OGX-011 (see materials
and methods) at 200-1200 nM are compared with control oligonucleotides. OGX-011 transfection at 800, 1000 and 1200 nM significantly
knocked down CLU expression (far right panels). B. Comparative viability of different ovarian cancer cells before and after CLU knock down are.
Cells were cultured in 96-well plates, then transfected either with CLU-siRNA or control siRNA twice. Twenty-four hours after last transfection,
cells were treated with TX. Seventy-two hours after drug addition at indicated doses, cell viability was estimated. Both KF-TX cells (1) and SKOV-
3-TX (2) showed enhanced TX-induced toxicity in CLU KD cells versus controls. C. Time-dependent FACS analysis demonstrating that CLU-siRNA
enhanced TX toxicity in KF-TX cells. KF-TX cells were transfected either with CLU-siRNA or control siRNA and challenged with TX dose of 200 nM
at indicated time periods. Representative DNA histograms show the apoptotic response to TX with and without CLU-siRNA transfection (1).
Annexin V staining of cells treated as in panel (1). Time-course quantification of the relative ratio of apoptotic cells at different time points in the
presence of CLU siRNA or controls when cells were challenged with TX (2).
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Page 10 of 14Figure 6 Targeting CLU by OGX-011 sensitizes ovarian cancer cells to TX treatment. A.Comparative viability of chemoresistant ovarian
cancer cells before and after CLU knock down by OGX-011. Cells were cultured in 96-well plates, then transfected either with CLU-siRNA or
control siRNA twice. Twenty-four hours after last transfection, cells were treated with TX. Seventy-two hours after drug addition at indicated
doses, cell viability was estimated. KF-TX cells showed enhanced TX-induced toxicity in CLU KD cells versus controls. B. A representative time-
dependent DNA histogram (FACS analysis) demonstrating that CLU KD by OGX-011 at 1200 nM enhanced TX toxicity in KF-TX cells. KF-TX cells
were transfected either with OGX-011 or control Oligonucleotide and then challenged with TX dose of 200 nM at indicated time periods (24 h,
36 h,48 h and 60 h). B. Results of Annexin V staining of cells pre-treated with OGX-011 at different concecntrations (400, 800 and 1200 nM) then
treated with TX (200 nM) for indicated time periods (24, 48 and 72 h). Quantification of the relative ratio of apoptotic cells at different time
points indicated the significant enhancement of TX toxicity by OGX-011. The maximum enhancement was obtained by 800 nM OGX-011 while
the conc. of 1200 nM did not show further significant improvement in toxicity. D. CLU knock down modulates cellular growth rate of ovarian
cancer cells. (1) KF-TX cells showed enhanced growth rate when transfected with CLU siRNA with regard to controls. KF-TX cells either pre-
transfected twice with CLU siRNA or control siRNA and then divided in 24 well plat in triplicates. Cell number was counted manually each 12 h
(2). Representative clonogenic assay shows that targeting CLU by siRNA (sh-CLU) increased TX-induced clonogenic toxicity in KF cells. In this
case, KF cells were either transfected with CLU short hairpin expressing vector (CLU-shRNA) or mock control alone and then cells were
challenged by increasing doses of TX starting from 2-5 nM for three weeks. The resistant colonies surviving drug stress were stained by Giemsa
after methanol fixation and pictures were taken with a digital camera..
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Page 11 of 14KF parental cells to study the effect of stable knock
down of CLU on the long treatment of TX. Under these
conditions, we proceeded to TX treatment with sub-
lethal but increasing doses (2-10 nM of TX) for three
weeks. Then, clonogenic ability over TX administration
was studied. Importantly, CLU-shRNA significantly
reduced the generation of TX-resistant clones if com-
pared with mock transfectants (Figure 6D.2) indicating
that s-CLU expression is necessary for ovarian cancer
cells to develop TX resistance probably to inhibit cell
growth.
Discussion
In the present study, we have shown that CLU expres-
sion is a prognosticator for ovarian cancer patients who
were treated with primary complete surgical staging and
adjuvant taxane/platinum combination chemotherapy in
early-stage disease. Prognostic significance of CLU
expression has been reported in different cancer types
in the literature. The expression level of CLU in renal
cancer cells was found to be closely associated with
pathological stage and grade of the tumor; and the over-
all and recurrence-free survival rate of patients with
strong CLU expression was significantly lower than that
of patients with weak expression [33]. CLU expression
levels correlated with tumor size, estrogen and proges-
terone receptor expression levels, and lymph node
metastasis in breast carcinoma [32]. Similarly, CLU has
been proposed to be a new potential prognostic and
predictive marker for colon carcinoma aggressiveness,
since overexpression of CLU is observed in highly
aggressive tumors as well as metastatic nodules [15].
However, prognostic significance of CLU expression
remains controversial for ovarian cancer patients. Recent
publication described that the average survival time of
the patients with CLU overexpression was significantly
shorter than those with normal CLU expression [26].
CLU expression was associated with survival of patients
with primary ovarian cancer (relative risk for overall sur-
vival 1.69; 95% confidence interval, 1.52 to 1.95 (P =
0.033)). On the contrary, it was reported that high
expression of CLU was related to favorable prognosis in
advanced-stage (stage III) serous ovarian cancer [28].
Although our observations were consistent with pre-
viously reported ones that s-CLU mediates cisplatin-
induced resistance in ovarian cancer [34], CLU expres-
sion was found not to be a prognostic factor among
patients with advanced-stage (stage III/IV) ovarian can-
cer in our patient cohort (data not shown). Moreover,
our study showed that s-CLU is well expressed in many
ovarian cancer cell lines assayed and resistant ovarian
cancer tissues. Additionally, through mechanisms not
yet elucidated, as a consequence of acquired resistance,
CLU biosynthesis is altered and up-regulated in ovarian
cancer cells.
Optimal surgery is a strong prognosticator for
advanced-stage ovarian cancer, which was also found in
our advanced-stage patient cohort (data not shown), and
it is widely accepted that complete cytoreduction is the
most important prognostic factor for ovarian cancer.
We found that immunohistochemical expression of
CLU showed prognostic significance for the patients
with early-stage (stage I/II) patients who underwent
complete cytoreduction as a primary surgery, whereas
histologic subtype and stage are not associated with
their survival. Perhaps, the response to front-line che-
motherapy might be one of the most important factors
for survival among the patients with early-stage disease.
Our result suggests that CLU is related to survival
because overexpression of CLU is related to chemoresis-
tance [35,36]. That is might be because CLU can result
in impaired survival for early-stage cases [26]. Alterna-
tively, overexpression of CLU might increase migration
and invasion capacity of ovarian cancer cells [27].
To improve the survival of ovarian cancer patients, we
need to develop new combination therapy of cytotoxic
drugs better than current standard regimen (TX/carbo-
platin; TC). However, the result of GOG182 to find
superior regimen to TC was negative, indicating that it
might be quite difficult to find new useful combination
therapy better than TC [37]. Thus, it is necessary to test
the efficacy of molecular targeting drugs such as bevaci-
zumab with or without cytotoxic agents, or the new
drugs to modulate sensitivity to platinums and/or tax-
anes for better survival.
S-CLU expression had changed upon acquisition of
TX-resistance and TX treatment in ovarian cancer cells
and tissues. SiRNA or OGX-011 administration caused
efficient depletion of CLU mRNA in vitro. Under these
conditions, TX stress induced apoptosis more efficiently
in CLU-depleted cells most probably because of
enhanced growth rate after s-CLU knock-down which
makes cells rapidly trapped in the G2/M arrest by TX
as a microtubule stabilizing agent. S-CLU may act as a
cytoprotective protein [38] and also possesses extracellu-
lar chaperone-like activity inducing phagocytosis by
nearby cells [39,9]. In this study, chemo-sensitivity
induced by CLU gene silencing was directly correlated
to the endogenous level of CLU protein expressed in a
given cell line, being particularly enhanced in KF-TX,
SKOV-3-TX, that express the highest levels of s-CLU.
An experimental system in which OVK18 cells were
genetically modified to specifically over-expression s-
CLU rendered cells TX-resistant. Thus, in our system s-
CLU seems essential for ovarian cancer cells to resist
TX. Similar results have been obtained in cervical
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Page 12 of 14cancer [40]. Thus, up-regulation of s-CLU might be a
candidate marker to predict ovarian cancer chemo-resis-
tance, while its reduction after drug administration may
predict chemo-response when tumor cells have high
endogenous CLU.
Importantly, our results support the idea that, s-CLU
is a stress-associated cytoprotective protein that is up-
regulated in an adaptive cell survival manner following
various cell death trigger including chemotherapy in
ovarian cancer cells as well as in most cancer cells
[41,35]. Therefore, novel therapeutic strategy of silen-
cing s-CLU expression to overcome chemoresistance
were suggested when cancer cells over-express s-CLU as
in lung [42], prostate [43], kidney [44] or breast [13]. In
the current study, we firstly demonstrated that OGX-
011, a second-generation antisense oligodeoxynuclotide
targeting the translation initiation site of human CLU
gene exon II with a long tissue half-life, can modulate
sensitivity to TX in an acquired TX-resistant ovarian
cancer cell line. OGX-011 improved the efficacy of che-
motherapy, radiation, and hormone withdrawal by inhi-
biting expression of CLU and enhancing apoptotic rates
in preclinical xenograft models of prostate, lung, renal
cell, breast, and other cancers [44-46].
Interference with the innate apoptotic activity is a
hallmark of neoplastic transformation and tumor forma-
tion. Modulation of the apoptotic cascade has been pro-
posed as a new approach for the treatment of cancer.
Phenoxodiol [47] and XIAP inhibitor [48] are currently
tested in clinical trials as chemosensitizer for chemore-
sistant tumors [49]. recently reported the result of the
phase II study of docetaxel and prednisone with or with-
out OGX-011 in patients with metastatic castration-
resistant prostate cancer. They have shown that combi-
nation of OGX-011 with docetaxel significantly
improved survival [49]. We do hope to test the efficacy
of OGX-011 as a chemosensitizer to standard cytotoxic
drugs for the patients with recurrent (resistant tumor)
and refractory ovarian cancer.
Conclusions
In summary, present study demonstrated that alterations
of s-CLU biogenesis are induced during development of
TX-resistance. These changes include overexpression
inside cells and subsequent secretion into media posi-
tively correlates to chemo-resistant phenotype. Immuno-
histochemical detection of overexpression of CLU in
early-stage (stage I/II) ovarian cancer tissues was signifi-
cantly related to poor survival, while none of other clini-
copathological factors analyzed were related to survival.
We conclude that CLU could be a potential molecular
marker to predict chemoresistance in patients with ovar-
ian cancer. Thus, CLU gene seems to be a key element
regulating chemo-response/chemo-resistance to TX.
This gene product might be a potential therapeutic tar-
get to overcome the resistance to TX and improve the
subsequent survival in ovarian cancer patients.
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